Impact of setup uncertainty in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with Peacock/IMRT

被引:27
作者
Ahmad, S
Vlachaki, MT
Teslow, TN
Amosson, CM
McGary, J
Teh, BS
Woo, SY
Butler, EB
Grant, WH
机构
[1] Dept Vet Affairs Med Ctr, Houston, TX USA
[2] Baylor Coll Med, Houston, TX 77030 USA
关键词
prostate cancer; IMRT; setup error;
D O I
10.1016/j.meddos.2004.10.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The purpose of this paper was to assess the effect of setup uncertainty on dosimetry of prostate, seminal vesicles, bladder, rectum, and colon in prostate cancer patients treated with Peacock intensity-modulated radiation therapy (IMRT). Ten patients underwent computed tomography (CT) scans using the "prostate box" for external, and an "endorectal balloon" for target immobilization devices, and treatment plans were generated (T1). A maximum of +/- 5-mm setup error was chosen to model dosimetric effects. Isodose lines from the T1 treatment plan were then superimposed on each patient's CT anatomy shifted by 5 mm toward the cephalad and caudal direction, generating 2 more dosimetric plans (H1 and H2, respectively). Average mean doses ranged from 74.5 to 74.92 Gy for prostate and 73.65 to 74.94 Gy for seminal vesicles. Average percent target volume below 70 Gy increased significantly for seminal vesicles, from 0.53% to 6.26%, but minimally for prostate, from 2.08% to 4.4%. Dose statistics adhered to prescription limits for normal tissues. Setup uncertainty had minimum impact on target dose escalation and normal tissue dosing. The impact of target dose inhomogeneity is currently evaluated in clinical studies. (C) 2005 American Association of Medical Dosimetrists.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 41 条
[1]
Prostate target volume variations during a course of radiotherapy [J].
Antolak, JA ;
Rosen, II ;
Childress, CH ;
Zagars, GK ;
Pollack, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (03) :661-672
[2]
PEACOCK(TM) - A SYSTEM FOR PLANNING AND ROTATIONAL DELIVERY OF INTENSITY-MODULATED FIELDS [J].
CAROL, MP .
INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY, 1995, 6 (01) :56-61
[3]
CAROL MP, 1993, 3D RAD TREATMENT PLA, P435
[4]
TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[5]
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial [J].
Dearnaley, DP ;
Khoo, VS ;
Norman, AR ;
Meyer, L ;
Nahum, A ;
Tait, D ;
Yarnold, J ;
Horwich, A .
LANCET, 1999, 353 (9149) :267-272
[6]
DIAZ AZ, 1996, INT J RADIAT ONCOL, V30, P323
[7]
DUTTENHAVER JR, 1983, CANCER, V51, P1599, DOI 10.1002/1097-0142(19830501)51:9<1599::AID-CNCR2820510908>3.0.CO
[8]
2-O
[9]
Clinical and financial issues for intensity-modulated radiation therapy delivery [J].
Grant, W ;
Woo, SY .
SEMINARS IN RADIATION ONCOLOGY, 1999, 9 (01) :99-+
[10]
GRANT W, 1996, TELETHERAPY PRESENT, P793